- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04692402
Feasibility Trial Evaluating Efficacy and Safety of Solitaire™ Thrombus Retrieval Device in the Management of Refractory Thrombus in Patients With Acute Coronary Syndrome (Solitaire)
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
We hypothesize that Solitaire device could be effectively and safely used as an adjunctive interventional technique in ACS patients found to have refractory thrombus during PCI.
- Primary Objectives To evaluate intra-procedure efficacy of using Solitaire in ACS patients with refractory thrombus.
- Secondary Objectives To evaluate clinical efficacy of using Solitaire in ACS patients with refractory thrombus, up to one year post-procedure.
To evaluate safety of using Solitaire in ACS patients with refractory thrombus.
The target enrolment is 51 patients diagnosed with STEMI, NSTEMI or UA and found to have refractory thrombus during PCI. Eligible patients will be identified at the ED or Inpatient ward of the 5 participating hospitals. The projected enrolment period is for two years and follow up for one year. A screening log will be maintained at each site to keep record of patients who were eligible for the study but not enrolled, to establish any selection bias.
Tipo di studio
Iscrizione (Anticipato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: cathy Haiyan li, Master Degree
- Numero di telefono: +65 63578388
- Email: Haiyan_LI@ttsh.com.sg
Backup dei contatti dello studio
- Nome: Iswarya Jayakumar, Degree
- Numero di telefono: 63578326
- Email: Iswarya_JAYAKUMAR@ttsh.com.sg
Luoghi di studio
-
-
-
Singapore, Singapore, 768828
- Reclutamento
- Khoo Teck Puat Hospital
-
Contatto:
- Boon Khim Lim
- Numero di telefono: (65)66023307
- Email: lim.boon.khim@ktph.com.sg
-
Investigatore principale:
- Dr Syed Saqib Imran
-
Singapore, Singapore, 119074
- Reclutamento
- National University Heart Centre Singapore (NUHCS)
-
Contatto:
- Jolene Leong
- Email: jolene_rachel_LEONG@nuhs.edu.sg
-
Investigatore principale:
- Dr Joshua LOH
-
Singapore, Singapore, 308433
- Reclutamento
- Tan Tock Seng Hospital (TTSH)
-
Contatto:
- Haiyan Li
- Numero di telefono: (65)63578388
- Email: Haiyan_LI@ttsh.com.sg
-
Investigatore principale:
- Dr Paul Jau Lueng Ong
-
Singapore, Singapore, 529889
- Reclutamento
- Changi General Hospital (CGH) Changi General Hospital
-
Contatto:
- Li Li
- Numero di telefono: (65)68502697
- Email: Li_Li@cgh.com.sg
-
Investigatore principale:
- Dr Yew Seong Goh
-
-
Singaproe
-
Singapore, Singaproe, Singapore, 169609
- Reclutamento
- National Heart Centre Singapore (NHCS)
-
Contatto:
- Aishah Toh
- Numero di telefono: (65)67042282
- Email: aishah.toh@nhcs.com.sg
-
Investigatore principale:
- Dr Aaron Sung Lung Wong
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Subjects meeting all of the inclusion criteria listed below will be included in this study:
Index event of ST segment elevation or non-ST segment elevation MI or Unstable Angina defined as:
Presentation to hospital with symptoms of myocardial ischemia (Chest pain or angina equivalent) lasting for ≥10 minutes at rest
AND 1 of the following:
- Persistent ST segment elevation ≥1mm (0.1 mV) in two or more contiguous limb leads or ≥2mm (0.2 mV) in ) in one or more contiguous precordial leads OR
- New or presumed new left bundle branch block (LBBB) OR
- ST segment depression ≥1mm (0.1 mV) in two or more contiguous leads (not known to be pre-existing or due to a known cause such as LV hypertrophy or digoxin) OR
- Troponin T or I greater than the laboratory upper normal limit.
Referred for urgent or emergency PCI AND Thrombus burden of TG 4 or above OR TIMI flow grade of 1 or less in at least one native infarct related artery following either
- Manual aspiration thrombectomy OR
- Balloon Angioplasty OR
- AngioJet RT OR
- Patient having deferred PCI due to heavy thrombus but continue to demonstrate recalcitrant thrombus upon repeat angiography.
Exclusion Criteria:
Subjects meeting any of the exclusion criteria listed below will be excluded from this study:
- Age ≤ 21 years
- Cardiogenic shock
- killip class 3 or above at presentation
Known relative contraindications for the use of Solitaire:
- Prior stent in infarct related artery
- Significant proximal stenosis OR Ostial lesion at angiography
- Extensive calcification
- Life expectancy less than six months due to non-cardiac condition
- Participants categorised as vulnerable subjects (ex: prisoners, pregnant women, and mentally disabled persons)
- Patients at high risk of being lost to follow up (ex: non-residents)
- Participation in any study with an investigational drug or device within the last 30 days
- Patients who are unable to provide informed consent prior to any procedure .
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Altro: open label
open label prospective feasibility trial.
|
After consent has been obtained, interventional cardiologist selects the proper solitaire device size per device-specific instructions for use.
Adjunctive intervention with Solitaire will be done with a maximum of 2 device deployments.
Do not perform more than three recovery attempts in the same vessel using the devices (Maximum of 2 attempts per device per subject).
Do not reposition each device more than two times.
TIMI flow, thrombus grade and myocardial blush grade will be assessed immediately upon completion of procedure.
If recanalization is deemed inadequate by the interventional cardiologist, rescue treatment will follow as per current clinical practice.
All other procedures followed will be as clinically indicated.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Rate of successful recanalization defined as an immediate post-procedure Thrombolysis in Myocardial Infarction (TIMI) flow of 2 or 3.
Lasso di tempo: immediate post-procedure
|
Primary Efficacy Endpoint
|
immediate post-procedure
|
Occurrence of any stroke
Lasso di tempo: immediate post-procedure up to 30 days
|
Occurrence of any stroke, defined as the presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours, from immediate post-procedure up to 30 days.
|
immediate post-procedure up to 30 days
|
Incidence of study device-related Serious Adverse Events (SAEs) up to 30 days.
Lasso di tempo: up to 30 days
|
Primary Safety Endpoint
|
up to 30 days
|
Incidence of emboli in new territory (ENT) at 24 hrs ± 8 hrs post procedure (ENT: Embolization territories outside of the target downstream territory).
Lasso di tempo: at 24 hours ± 8 hours post procedure
|
Primary Safety Endpoint
|
at 24 hours ± 8 hours post procedure
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Rate of successful thrombus resolution defined as an immediate post-procedure thrombus burden of thrombus grade (TG) 1 or less
Lasso di tempo: immediate post-procedure
|
Secondary Endpoints
|
immediate post-procedure
|
Rate of successful recanalization defined as a reduction in corrected TIMI frame count after use of the Solitaire device.
Lasso di tempo: immediate post-procedure
|
Secondary Endpoints
|
immediate post-procedure
|
Rate of successful myocardial perfusion defined as an immediate post-procedure myocardial blush grade (MBG) of 2 or more
Lasso di tempo: immediate post-procedure
|
Secondary Endpoints
|
immediate post-procedure
|
Rate of device success defined as successful delivery and retrieval of the device without complication
Lasso di tempo: immediate post- procedure
|
Secondary Endpoints
|
immediate post- procedure
|
Occurrence of major adverse cardiac and cerebrovascular events (MACCE)
Lasso di tempo: up to one year post-procedure
|
Occurrence of major adverse cardiac and cerebrovascular events (MACCE), defined as composite of all cause death, myocardial infarction, target vessel revascularisation or stroke, up to one year post-procedure.
|
up to one year post-procedure
|
All-cause mortality through 90 days post procedure.
Lasso di tempo: 90 days post procedure
|
Secondary Endpoints
|
90 days post procedure
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Paul Jau Lueng Ong, Paul Ong Jau Lueng
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- DSRB 2018/00865
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .